Format

Send to

Choose Destination
PLoS One. 2016 Jan 13;11(1):e0147113. doi: 10.1371/journal.pone.0147113. eCollection 2016.

Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.

Author information

1
Department of Pharmacology, School of Medicine, The University of North Carolina, Chapel Hill, NC, United States of America.
2
Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC, United States of America.
3
ProHealth Care Regional Cancer Center, Waukesha, WI, United States of America.
4
Department of Medicine, Division of Medical Oncology, University of Indiana, Indianapolis, IN, United States of America.
5
Department of Surgery, Division of Surgical Oncology and Endocrinology, The University of North Carolina, Chapel Hill, NC, United States of America.

Abstract

There is currently tremendous interest in developing anti-cancer therapeutics targeting cell signaling pathways important for both cancer cell metabolism and growth. Several epidemiological studies have shown that diabetic patients taking metformin have a decreased incidence of pancreatic cancer. This has prompted efforts to evaluate metformin, a drug with negligible toxicity, as a therapeutic modality in pancreatic cancer. Preclinical studies in cell line xenografts and one study in patient-derived xenograft (PDX) models were promising, while recently published clinical trials showed no benefit to adding metformin to combination therapy regimens for locally advanced and metastatic pancreatic cancer. PDX models in which patient tumors are directly engrafted into immunocompromised mice have been shown to be excellent preclinical models for biomarker discovery and therapeutic development. We evaluated the response of four PDX tumor lines to metformin treatment and found that all four of our PDX lines were resistant to metformin. We found that the mechanisms of resistance may occur through lack of sustained activation of adenosine monophosphate-activated protein kinase (AMPK) or downstream reactivation of the mammalian target of rapamycin (mTOR). Moreover, combined treatment with metformin and mTOR inhibitors failed to improve responses in cell lines, which further indicates that metformin alone or in combination with mTOR inhibitors will be ineffective in patients, and that resistance to metformin may occur through multiple pathways. Further studies are required to better understand these mechanisms of resistance and inform potential combination therapies with metformin and existing or novel therapeutics.

PMID:
26760500
PMCID:
PMC4711922
DOI:
10.1371/journal.pone.0147113
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center